IMAXT and Rosetta: the teams that took on the 3D tumour mapping challenge
Learn about how IMAXT and Rosetta have been at the forefront of the spatial biology revolution.
Impact
Changing the landscape of cancer research
From transforming our understanding of how mutations cause cancer to developing cutting-edge technologies to comprehensively map tumours, Cancer Grand Challenges teams are driving impact against some of the toughest challenges in cancer.
In 2017, we awarded over $90m of funding to four teams to take on our first round of challenges — 3D tumour mapping, lethal versus non-lethal cancers and unusual mutation patterns.
In the seven years that followed, these teams made incredible progress; changing ways of thinking in their fields and paving the way for future research, to ultimately change outcomes for people with cancer.
Learn more about their impact below.
Discover: A year of scientific creativity
Cancer Grand Challenges' annual progress magazine, highlighting the latest progress from funded teams, stories from the community and more.
Read the magazine 